Clinical Trial Update: Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating tomivosertib (eFT-508) in combination with PD-1/PD-L1 inhibitors for solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Tomivosertib (tomivosertib)

Snippet

Sponsor: Effector Therapeutics | Conditions: Solid Tumors | Phase 2 | Status: COMPLETED